Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF 48 14-Day RSI is 58.88 as of Jul. 29, 2026. GuruFocus rates ZLDPF with a GF Score™ of 48/100. The stock has 3 warning signs investors should review. Among 1,421 Biotechnology companies, Zealand Pharma AS ranks worse than 89.87% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Zealand Pharma AS's 14-Day RSI or its related term are showing as below:
ZLDPF's 14-Day RSI is ranked worse than 89.87% of 1421
companies
in the Biotechnology industry
Industry Median: 43.76
vs ZLDPF: 58.88
Zealand Pharma AS (OTCPK:ZLDPF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Zealand Pharma AS 14-Day RSI Related Terms
ZLDPF vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, Zealand Pharma AS's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's 14-Day RSI falls into.
Zealand Pharma AS (OTCPK:ZLDPF) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a 14-Day RSI of 58.88 as of Jul. 29, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #1277 out of 1421 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Zealand Pharma AS's 14-Day RSI too high?
Zealand Pharma AS's current 14-Day RSI is 58.88. The Biotechnology industry median 14-Day RSI is 43.76. Zealand Pharma AS's value of 58.88 is 34.6% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #1277 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #1277 out of 1421 companies for 14-Day RSI. This places Zealand Pharma AS in the lower half of its industry. The industry median 14-Day RSI is 43.76. Zealand Pharma AS's value of 58.88 is 34.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 43.76, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current 14-Day RSI of 58.88 is 34.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median 14-Day RSI is 43.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current 14-Day RSI is 58.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (ZLDPF) has a current 14-Day RSI of 58.88. The current 14-Day RSI is 58.88 and 34.6% above the Biotechnology industry median of 43.76. Zealand Pharma AS's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current 14-Day RSI is 58.88 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
48GF Score
Get the complete analysis for ZLDPF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
